CU23897B1 - Péptido para la terapia del cáncer - Google Patents

Péptido para la terapia del cáncer

Info

Publication number
CU23897B1
CU23897B1 CU2010000113A CU20100113A CU23897B1 CU 23897 B1 CU23897 B1 CU 23897B1 CU 2010000113 A CU2010000113 A CU 2010000113A CU 20100113 A CU20100113 A CU 20100113A CU 23897 B1 CU23897 B1 CU 23897B1
Authority
CU
Cuba
Prior art keywords
peptide
cancer therapy
increase
nuclear localization
cancer
Prior art date
Application number
CU2010000113A
Other languages
English (en)
Other versions
CU20100113A7 (es
Inventor
Vallespi Maribel Guerra
Masó Julio Raúl Fernández
Lasa Alexis Musacchio
Valdés Jeovanis Gil
Acosta Osvaldo Reyes
Argüelles Brizaida Maylin Oliva
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU2010000113A priority Critical patent/CU23897B1/es
Priority to ARP110101831A priority patent/AR081259A1/es
Priority to EP11728172.5A priority patent/EP2578227B1/en
Priority to US13/700,286 priority patent/US8729226B2/en
Priority to JP2013512751A priority patent/JP5827322B2/ja
Priority to BR112012030668-5A priority patent/BR112012030668B1/pt
Priority to DK11728172.5T priority patent/DK2578227T3/en
Priority to UAA201215130A priority patent/UA112522C2/uk
Priority to RU2012157289/10A priority patent/RU2577993C2/ru
Priority to MX2012013923A priority patent/MX2012013923A/es
Priority to AU2011260745A priority patent/AU2011260745B2/en
Priority to PCT/CU2011/000003 priority patent/WO2011150897A2/es
Priority to CN201180026853.7A priority patent/CN102917725B/zh
Priority to KR1020127033777A priority patent/KR101847170B1/ko
Priority to CA2799066A priority patent/CA2799066C/en
Publication of CU20100113A7 publication Critical patent/CU20100113A7/es
Priority to ZA2012/08905A priority patent/ZA201208905B/en
Publication of CU23897B1 publication Critical patent/CU23897B1/es
Priority to US14/075,276 priority patent/US9145554B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

En la invención se describe la optimización de un péptido, proveniente de la secuencia HARIKPTFRRLKWKKYKGKFW, para incrementar la localización nuclear de la proteína COMMD1 y , de esa forma, aumentar el efecto antitumoral de dicho péptido. Por lo tanto, la presente invención revela un péptido para el tratamiento del cáncer mediante el incremento de la localización nuclear de la proteína COMMD1, lo cual se asocia con la disminución o bloqueo de la proliferación de la célula de cáncer.
CU2010000113A 2010-05-31 2010-05-31 Péptido para la terapia del cáncer CU23897B1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer
ARP110101831A AR081259A1 (es) 2010-05-31 2011-05-27 Metodo para la terapia del cancer
MX2012013923A MX2012013923A (es) 2010-05-31 2011-05-31 Metodo para la terapia del cancer.
PCT/CU2011/000003 WO2011150897A2 (es) 2010-05-31 2011-05-31 Método para la terapia del cáncer
JP2013512751A JP5827322B2 (ja) 2010-05-31 2011-05-31 癌の治療方法
BR112012030668-5A BR112012030668B1 (pt) 2010-05-31 2011-05-31 Peptídeos, composição farmacêutica, e combinação farmacêutica
DK11728172.5T DK2578227T3 (en) 2010-05-31 2011-05-31 METHOD OF CANCER THERAPY
UAA201215130A UA112522C2 (uk) 2010-05-31 2011-05-31 Спосіб терапії злоякісної пухлини
RU2012157289/10A RU2577993C2 (ru) 2010-05-31 2011-05-31 Способ терапии злокачественной опухоли
EP11728172.5A EP2578227B1 (en) 2010-05-31 2011-05-31 Cancer therapy method
AU2011260745A AU2011260745B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
US13/700,286 US8729226B2 (en) 2010-05-31 2011-05-31 Cancer therapy method
CN201180026853.7A CN102917725B (zh) 2010-05-31 2011-05-31 用于癌症治疗的肽
KR1020127033777A KR101847170B1 (ko) 2010-05-31 2011-05-31 암 치료 방법
CA2799066A CA2799066C (en) 2010-05-31 2011-05-31 Method for cancer therapy
ZA2012/08905A ZA201208905B (en) 2010-05-31 2012-11-26 Cancer therapy method
US14/075,276 US9145554B2 (en) 2010-05-31 2013-11-08 Cancer therapy method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer

Publications (2)

Publication Number Publication Date
CU20100113A7 CU20100113A7 (es) 2012-06-21
CU23897B1 true CU23897B1 (es) 2013-05-31

Family

ID=45067129

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000113A CU23897B1 (es) 2010-05-31 2010-05-31 Péptido para la terapia del cáncer

Country Status (16)

Country Link
US (2) US8729226B2 (es)
EP (1) EP2578227B1 (es)
JP (1) JP5827322B2 (es)
KR (1) KR101847170B1 (es)
CN (1) CN102917725B (es)
AR (1) AR081259A1 (es)
AU (1) AU2011260745B2 (es)
BR (1) BR112012030668B1 (es)
CA (1) CA2799066C (es)
CU (1) CU23897B1 (es)
DK (1) DK2578227T3 (es)
MX (1) MX2012013923A (es)
RU (1) RU2577993C2 (es)
UA (1) UA112522C2 (es)
WO (1) WO2011150897A2 (es)
ZA (1) ZA201208905B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2105567C1 (ru) * 1995-12-01 1998-02-27 Сергей Юрьевич Родионов Способ лечения злокачественных опухолей
CU23582A1 (es) * 2006-02-24 2010-10-30 Ct Ingenieria Genetica Biotech Péptidos con capacidad anti-tumoral e inmunomoduladora
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica

Also Published As

Publication number Publication date
US8729226B2 (en) 2014-05-20
EP2578227B1 (en) 2016-12-28
WO2011150897A3 (es) 2012-03-15
ZA201208905B (en) 2013-07-31
US20140206621A1 (en) 2014-07-24
AU2011260745A1 (en) 2012-12-06
EP2578227A2 (en) 2013-04-10
MX2012013923A (es) 2013-01-24
CN102917725A (zh) 2013-02-06
CN102917725B (zh) 2014-09-17
RU2577993C2 (ru) 2016-03-20
AU2011260745B2 (en) 2014-08-07
BR112012030668A2 (pt) 2020-08-25
US20130224313A1 (en) 2013-08-29
CA2799066A1 (en) 2011-12-08
CA2799066C (en) 2019-07-23
US9145554B2 (en) 2015-09-29
DK2578227T3 (en) 2017-03-27
RU2012157289A (ru) 2014-07-20
JP2013530162A (ja) 2013-07-25
AR081259A1 (es) 2012-07-18
KR101847170B1 (ko) 2018-05-28
JP5827322B2 (ja) 2015-12-02
BR112012030668B1 (pt) 2022-03-29
WO2011150897A2 (es) 2011-12-08
KR20130089167A (ko) 2013-08-09
CU20100113A7 (es) 2012-06-21
UA112522C2 (uk) 2016-09-26

Similar Documents

Publication Publication Date Title
GT201700033A (es) Anticuerpos anti tigit
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
CL2019000844A1 (es) Compuesto de piridina.
UY34780A (es) Vectores virales para el tratamiento de distrofia retiniana
GT201500051A (es) Inhibidores de glucosilceramida sintasa
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
CO6690792A2 (es) Análogos de nucleotidos sustituidos
GT201300215A (es) Inhibidores de glucosilceramida sintasa
EA201400178A1 (ru) Лечение рака молочной железы
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
MX365403B (es) Peptidos y metodos para usarlos.
UY34178A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos.
EP2852410A4 (en) TREATMENT OF CANCER BY MANIPULATING THE IMMUNE SYSTEM
IL274663B1 (en) Cancer therapy through mek dual signaling deregulation
CL2015002612A1 (es) Oligonucletotidos antisentido para el tratamiento de células madre del cáncer.
EA201300611A1 (ru) Меченныелютецием аналоги бомбезина для лучевой терапии
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)
AU2011261249A8 (en) Cancer treatment with wortmannin analogs

Legal Events

Date Code Title Description
FG Grant of patent